

Freeze-dried kit formulation of ¹⁷⁷Lu- and ⁹⁰Y-labeled immunoconjugates of Trastuzumab – formulation and characterization



(< 25% of released 90 Y),

Abstract ID n. 90

Marija Sterjova Arev^{1,2}, Predrag Džodić², Petre Makreski³, Drina Janković⁴, Katarina Davalieva⁵, Marija Mirković⁴, Sanja Kiprijanovska⁵, Magdalena Radović⁴, Aleksandar Dimovski^{5,6}, Emilija Janevik-Ivanovska^{1*}

¹Faculty of Medical Sciences, Goce Delcev University Stip, Republic of North Macedonia

²Faculty of Medicine, Department of Pharmacy, University of Niš, Nis, Serbia
³Institute of Chemistry, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University, Republic of North Macedonia

⁴Vinča Institute of Nuclear Sciences, University of Belgrade, Serbia

⁵Research Centre for Genetic Engineering and Biotechnology "Georgi D Efremov", Macedonian Academy of Sciences and Arts, Skopje, Republic of North Macedonia

⁶Faculty of Pharmacy, University "St. Cyril and Methodius", Skopje, Republic of North Macedonia

Introduction

Trastuzumab is a humanized IgG1 monoclonal antibody for treatment of HER2 positive breast cancer. Due to the significant potency in various malignancies and easy detection of radioactivity with outside scintigraphy, radioimmunoconjugates have become a part of many clinical trials.

The aim of this study is to formulate a stable freeze-dried trastuzumab-immunoconjugates with bifunctional chelators (BFCAs): *p-SCN-Bn-DTPA*, *p-SCN-Bn-DOTA*, *p-SCN-Bn-1B4M-DTPA*, to evaluate and provide valuable molecular structure information including verification of changes after antibody manipulation and exposure to stress conditions during the processes of conjugation, freeze-drying and labeling with non-radioactive LuCl₃ and YCl₃ and radioactive ¹⁷⁷LuCl₃ and ⁹⁰YCl₃.

Material and Methods



Conclusion

Our study shows successful formulation of stable radioimmunoconjugates which makes this proposed freeze-dried kit as potential radiopharmaceutical *in vivo* investigations.